Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Gordon Research Conference on Immunochemistry & Immunobiology
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Glatiramer acetate ameliorates experimental autoimmune neuritis.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Cyclophosphamide
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
New York Academy of Sciences: T Cells at the Interface of Immune-CNS Cross-Talk
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
Oligodendrocyte death results in immune-mediated CNS demyelination.

Pages